Cytotoxicity of Three Novel Fluoropyrimidines in Cultured L1210 Murine Lymphocytic Leukemia Cells

Springer Science and Business Media LLC - 1990
Annette M. Shipp1, Mark H. Holshouser1, Paul W. Ferguson1
1Division of Pharmacology and Toxicology, School of Pharmacy, Northeast Louisiana University, Monroe

Tóm tắt

Cultured L1210 murine lymphocytic leukemia cells were used to compare metabolic activation and cytotoxicity of 5-fluorouracil (FU), Ftorafur (FT), and three novel FU-sulfur analogues. These analogues, l-(2′-tetrahydrothienyl)-5-fluorouracil (FUS), l-(2′-tetrahydrothienyl)-5-fluorouracil-l′-oxide (FUSO), and 1-(2′-tetrahydrothienyl)-5-fluorouracil-l′-l′-dioxide (FUSO2), have yet to be fully evaluated for potential therapeutic value based on in vitro cytotoxicity. The role of these FU analogues as prodrugs was evaluated by comparing metabolism of normal pyrimidine pathways and activation by hepatic mixed function oxidases (MFO). Significant differences in biochemical activity and cytotoxicity were measured between FU and FU analogues. FU and FU analogues were cytotoxic to L1210 cells (63–92% growth inhibition of 100 µM concentrations after 72 hr of incubation). However, at equimolar concentrations cytotoxicity of the FU analogues after MFO activation (56–66% growth inhibition) was greater than FU (47% growth inhibition). Hypoxanthine, a purine precursor, did not significantly alter fluoropyrimidine cytotoxicity with or without MFO. Thymidine and uridine, pyrimidine precursors, reduced FT and FUS cytotoxicities in the presence (27, 40%) and absence (25, 15%) of MFO but did not modify FU, FUSO, or FUSO2 cytotoxicities.

Từ khóa


Tài liệu tham khảo

B. A. Chabner, Y. Rustum, and H. Slocum. Cancer Treat. Rep. 65:27–31 (1981).

R. D. Armstrong and R. B. Diasio. Cancer Res. 40:3333–3338 (1980).

D. Roberts, P. Franklin, G. Odom, and C. Peck. Mol. Pharmacol. 22:760–765 (1982).

A. Rosowsky, S. H. Kim, and M. Wick. J. Med. Chem. 24:1177–1181 (1981).

M. A. Friedman and R. J. Ignoffo. Cancer Treat. Rev. 7:205–213 (1980).

C. Heidelberger, P. Dannenberg, and R. Moran. Adv. Enzymol. 54:58–119 (1983).

S. Fugimoto, T. Akao, and B. Itoh. Cancer Res. 36:33–36 (1976).

A. M. Cohen. Drug Metab. Disp. 3:303–308 (1975).

Y. M. Sayed and W. Sadee. Cancer Res. 43:4039–4044 (1983).

Y. M. Sayed and W. Sadee. Bioch. Pharmacol. 31:3006–3008 (1982).

J. L. Au and W. Sadee. Cancer Res. 40:2814–2819 (1980).

M. H. Holhouser, A. M. Shipp, and P. W. Ferguson. J. Med. Chem. 28:242–245 (1985).

B. Schultze, W. Jellinghaus, and G. Weis. J. Cancer Clin. Oncol. 100(l):25–40 (1981).

M. A. Mulkins and C. Heidelberger. Cancer Res. 42:965–973 (1980).

E. K. Bhuyan, T. J. Fraser, and K. J. Day. Cancer Res. 37:1057–1083 (1977).

A. Piper, S. Nott, W. Mackinnon, and M. Tattersall. Cancer Res. 43:5701–5705 (1983).

B. Ullman and J. Kirsch. Mol. Pharmacol. 15:357–366 (1978).

L. Ott. An Introduction to Statistical Methods and Data Analysis, 3rd ed., PWS-Kent, Boston, 1988.

F. Kanzawa, A. Hoshi, and K. Kuretani. Clin. Oncology 25:85–90 (1980).

P. M. Schwartz and R. E. Handschumacher. Cancer Res. 39:3095–3101 (1979).

M. Yoshida, A. Hoshi, and K. Kuretani. Biochem. Pharmacol. 27:2979–2982 (1978).

A. A. Piper and R. M. Fox. Cancer Res. 42:3753–3760 (1982).

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả